OCUL has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
OCUL has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Ocular Therapeutix's Revenue per Share for the three months ended in Dec. 2023 was $0.16.
During the past 12 months, Ocular Therapeutix's average Revenue per Share Growth Rate was 9.60% per year. During the past 3 years, the average Revenue per Share Growth Rate was 33.70% per year. During the past 5 years, the average Revenue per Share Growth Rate was 73.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.
During the past 12 years, the highest 3-Year average Revenue per Share Growth Rate of Ocular Therapeutix was 192.40% per year. The lowest was -11.50% per year. And the median was 47.95% per year.
For the Biotechnology subindustry, Ocular Therapeutix's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Ocular Therapeutix's 3-Year Revenue Growth Rate distribution charts can be found below:
* The bar in red indicates where Ocular Therapeutix's 3-Year Revenue Growth Rate falls into.
This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.
Ocular Therapeutix (NAS:OCUL) 3-Year Revenue Growth Rate Explanation
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.
Thank you for viewing the detailed overview of Ocular Therapeutix's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.
Summer Road Llc | 10 percent owner | 207 6TH STREET, WEST PALM BEACH FL 33401 |
Antony C. Mattessich | director | C/O OCULAR THERAPEUTIX, INC., 34 CROSBY DR., SUITE 105, BEDFORD MA 01730 |
Adrienne L Graves | director | 125 STONE MOUNTAIN CIRCLE, NAPA CA 94558 |
Rabia Gurses Ozden | officer: Chief Medical Officer | C/O AKOUOS, INC., 645 SUMMER STREET SUITE 200, BOSTON MA 02210 |
Philip C. Strassburger | officer: General Counsel | 24 CROSBY DRIVE, BEDFORD MA 01730 |
Donald Notman | officer: Chief Financial Officer | C/O OCULAR THERAPEUTIX, INC., 15 CROSBY DRIVE, BEDFORD MA 01730 |
Christopher G White | officer: Chief Business Officer | C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451 |
Jeffrey S. Heier | director | C/O OCULAR THERAPEUTIX, INC., 34 CROSBY DR., SUITE 105, BEDFORD MA 01730 |
Merilee Raines | director | IDEXX LABORATORIES, INC., ONE IDEXX DRIVE, WESTBROOK ME 04092 |
Lindstrom Richard L Md | director | 2811 WESTWOOD PL, WAYZATA MN 55391 |
Opaleye Management Inc. | 10 percent owner | ONE BOSTON PLACE, SUITE 2600, BOSTON MA 02108 |
Patricia Kitchen | officer: Chief Operations Officer | C/O OCULAR THERAPEUTIX, INC., 15 CROSBY DRIVE, BEDFORD MA 01730 |
Leslie J. Williams | director | C/O OCULAR THERAPEUTIX, INC., 15 CROSBY DRIVE, BEDFORD MA 01730 |
Seung Suh Hong | director | C/O OCULAR THERAPEUTIX, INC., 15 CROSBY DRIVE, BEDFORD MA 01730 |
Amarpreet Sawhney | director, 10 percent owner, officer: President and CEO | C/O OCULAR THERAPEUTIX, INC., 36 CROSBY DRIVE, SUITE 101, BEDFORD MA 01730 |
From GuruFocus
By sperokesalga sperokesalga • 06-01-2023
By Stock market mentor Stock market mentor • 01-06-2023
By sperokesalga sperokesalga • 02-11-2023
By sperokesalga sperokesalga • 02-28-2023
By Business Wire Business Wire • 07-25-2022
By Marketwired • 07-12-2023
By Business Wire Business Wire • 08-10-2022
By GlobeNewswire GlobeNewswire • 06-11-2023
By Marketwired • 08-09-2023
By Business Wire Business Wire • 11-08-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.